Company profile
Biotricity, Inc.
OTC: BTCY · Healthcare · Medical - Devices
#594 of 1,422 Healthcare companies by revenue60th-percentile growth
EA Score
——FH —DQ 28GM —SS 44
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, operating margin · ↓ balance-sheet leverage, filing timeliness
Methodology →Revenue TTM
$15.5M
Rev growth YoY (TTM)
+16.5%
Net income (FY)
-$8.4M
Employees
46
as of 2026-08-24
Market cap
$2.6M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$13.8M$13.8M2025
Net income-$8.4M-$8.4M2025
Operating income-$2.4M-$2.4M2025
Total assets$5.6M$5.6M2025
Liabilities$35.7M$35.7M2025
Equity-$32.0M-$32.0M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Technology Fees91%
Device Sales9%
By geography
Not disclosed.
The read
What is Biotricity, Inc.’s revenue?
Biotricity, Inc. booked $13.8M in FY2025 revenue, growing 14% year over year — faster than most Healthcare companies we track, at a -61.1% net margin.
Peers · Healthcare
Arbutus Biopharma Corp61CHealthcare Triangle, Inc.40DPyxis Oncology, Inc.28DCV Sciences, Inc.56CHyperfine, Inc.44DCapsoVision, Inc.37DNeighbors
San Mateo →Key facts
CEOWaqaas Al-Siddiq
SectorHealthcare
IndustryMedical - Devices
HeadquartersRedwood City, CA
ExchangeOTC: BTCY
Employees46
IPO date2018-02-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.